News|Articles|November 17, 2026

From Keytruda biosimilar to novel ADC: Samsung Bioepis’ 2-track oncology strategy

Author(s)Lauren Gordon
Listen
0:00 / 0:00

Key Takeaways

  • FDA Fast Track for SBE303 enables increased regulatory interactions and potential expedited review pathways, but provides no assurance of approval or clinical benefit in the ongoing first-in-human phase 1 trial.
  • SBE303 targets Nectin-4 with a novel topoisomerase I inhibitor payload and in-house linker, positioned to address dose-limiting toxicity and narrow therapeutic index challenges seen with some Nectin-4 ADC approaches.
SHOW MORE

SBE303, a Nectin-4 ADC for previously treated bladder cancer, is in phase 1 as the company advances SB27, its proposed Keytruda biosimilar.

Though Samsung Bioepis is best known for producing biosimilars, the company recently received FDA Fast Track designation for SBE303, an experimental cancer drug. SBE303 is an antibody-drug conjugate (ADC), essentially an antibody with a potent cancer-killing drug attached to it, and it is the company’s first novel ADC. It is being studied in adults with locally advanced or metastatic urothelial cancer (bladder cancer that has spread) who have already been treated with enfortumab vedotin (Padcev). Padcev also targets Nectin-4, but it carries a different payload.

SBE303 is in its first human trial (phase 1, NCT07524348), so there are no data yet on whether it works. The FDA granted the Fast Track designation in October. It allows more frequent interaction with the agency and could lead to a faster review, but it does not guarantee approval.

“The FDA’s Fast Track designation for SBE303 reflects the critical unmet medical need in patients with advanced solid tumors and recognizes the therapeutic rationale of targeting Nectin-4 with our next-generation ADC candidate,” Byoungin Jung, vice president and regulatory affairs team leader at Samsung Bioepis, said in a news release. “This designation establishes an important regulatory framework for our program, enabling closer dialogue and more frequent interactions with the Agency as our global Phase 1 study advances. We look forward to working collaboratively with the FDA to guide our clinical development program efficiently and advance SBE303 through each stage of evaluation.”

The company is now working on two tracks in oncology: a proposed biosimilar to Keytruda (SB27) and an original drug for patients whose cancer progresses after enfortumab vedotin, which is often given with Keytruda as first-line treatment.

How SBE303 works

SBE303 targets Nectin-4 and carries a topoisomerase I inhibitor payload. According to Samsung Bioepis, existing ADCs that target Nectin-4 can be limited by a narrow therapeutic index and side effects that restrict how much of the drug patients can receive. The company says SBE303 is designed to widen that margin by pairing a highly specific antibody against Nectin-4 with a new topoisomerase I inhibitor payload, joined by the company’s own linker technology.

Where SB27, the company’s Keytruda biosimilar, fits

In interim phase 3 results presented at the Society for Immunotherapy of Cancer (SITC) annual meeting, SB27 showed an objective response rate of 34.6% at week 24, compared with 37.9% for Keytruda. That difference fell within the trial’s predefined margin for equivalence.

SB27 was studied in lung cancer, and SBE303 is being studied in bladder cancer, but together the 2 programs show Samsung Bioepis building a cancer portfolio on 2 tracks. Keytruda is often given with Padcev as the first treatment for advanced bladder cancer. If SB27 is approved and its use is extended to Keytruda’s other indications, it could compete in that first-line setting, while SBE303 is aimed at patients who progress after Padcev. The company could eventually have products at 2 points in the same disease, though that remains hypothetical.

“Trust in oncology biosimilars is already proven across established antibodies in breast, lung and colorectal cancers,” a Samsung Bioepis representative told Managed Healthcare Executive. “SB27 builds on that precedent with robust Phase 3 NSCLC data confirming equivalent response rates with comparable safety and immunogenicity profiles to reference pembrolizumab, which can give clinicians confidence in using SB27. Biosimilars have a proven track record of generating significant healthcare savings, as documented annually by industry bodies like AAM [the Association for Accessible Medicines]. We believe SB27 can bring that same economic value and sustainability to pembrolizumab treatment.”

What’s next for Samsung Bioepis

Samsung Bioepis expects to present final progression-free and overall survival results for SB27 and publish the full manuscript next year. Data from patients who continued SB27 for up to 100 weeks will be reported separately. The company declined to comment on when it plans to file SB27 with the FDA or whether it will seek an interchangeability designation, which would allow pharmacists to substitute it for Keytruda without a new prescription.


Related to this article